Collaborating to share evidence-based COVID-19 information across lung cancer patient advocacy groups

Dr. Amy C. Moore
Director, Science & Research
GO₂ Foundation for Lung Cancer
Disclosures

I have no disclosures related to this presentation
Globally, there were an estimated 2.1 million lung cancer cases and 1.8 million deaths in 2018.

The novel coronavirus, SARS-CoV-2, causes a unique syndrome, COVID-19.

Lung cancer patients are at a higher risk of developing a severe form of COVID-19.
There is a need to provide up-to-date, scientifically accurate, and curated information on COVID-19.
Lung cancer advocacy groups in the US have come together to address this need

First joint advocacy statement released by 5 organizations

WHO declares COVID-19 a pandemic

First IASLC “Lung Cancer Considered” podcast on COVID-19 with advocates and experts

First GO2 Foundation Rapid Response Living Room on the importance of collaboration

IASLC podcast on impact of COVID-19 on basic and clinical lung cancer research with scientists and advocates

March 3

March 11

March 31

April 7

May 26
Metrics reveal a large reach online

- Between 5 advocacy groups, online posts receive more than 34,000 views across different social media platforms.
- First podcast received twice the number of listens compared to the average of pre-COVID-19 podcasts on IASLC and Soundcloud.
Lung cancer community finds updates timely and helpful

- Rapid evaluation survey open for 5 days online
- 83 respondents
  - 75% with stage III/IV lung cancer and 50% above the age of 60

Are you aware of joint statement?
- 67%

Did you find statements helpful?
- 80%

“Consistent information. It gives me more confidence in the information because all of the groups are coming together, rather than being motivated by a selfish objective from one organization. More eyes on the single goal of keeping lung cancer patients healthy & informed.”

“It demonstrates a common care and concern for lung cancer patients during this challenging time. There is also value in the groups combining resources to provide the best possible information to patients.”

An ACR Virtual Meeting
COVID-19 AND CANCER
July 20-22, 2020 | #AACRCOVID | AACR.org
Survey reveals that community finds information on accessing care during COVID-19 most useful

- Effect of the pandemic on lung cancer diagnosis, treatment, clinical trials: 62%
- COVID-19 treatments and vaccines: 54%
- Effect of the pandemic on lung cancer research: 54%
- Who is likely to have a severe case of COVID-19: 52%
- What do we know about developing immunity to COVID-19: 46%
- How to reduce risk of COVID-19 infection: 44%
- Known COVID-19 symptoms and how it affects different parts of the body: 44%
- What to do if you suspect you have or had COVID-19: 42%

---

An ACR Virtual Meeting
COVID-19 AND CANCER
July 20-22, 2020 | #AACRCOVID | AACR.org
Actualización de la Declaración Conjunta de los grupos de lucha contra el cáncer de pulmón sobre el COVID-19 para la semana del 13 al 19 de abril del 2020

A partir del 11 de abril del 2020, los Centros para el Control y la Prevención de Enfermedades (CDC) reportan 492,416 casos de COVID-19 y 18,559 muertes asociadas. Los Estados Unidos tienen ahora el mayor número de casos confirmados de COVID-19 en el mundo. Estas cifras pueden ser una subestimación de la verdadera carga de la enfermedad debido a la falta de pruebas y a la alta proporción de personas asintomáticas pero infecciosas.

Instamos a todos a continuar con el distanciamiento social: ¡está funcionando!
Conclusions

• COVID-19 presents a unique threat to the lung cancer community
• Lung Cancer PAGs rapidly mobilized to deliver curated, evidence-based information
• Updates achieved high reach, were well-received and have gone global
• Patients most concerned about access to COVID-19 and LC treatment